Since the concept of GIST was proposed in 1983, the diagnosis and treatment of GIST in China have continuously progress. Over the two decades from 1990 to 2010, the diagnosis and treatment of GIST had achieved a foundation of development through the collective efforts of GIST scholars, from the first pathological review to the first expert consensus. The period from 2010 to 2020 marked rapid development. Besides the updates of expert consensus, other relevant expert consensus was published regarding pathology, surgery, targeted therapy, therapeutic drug monitoring, and patient' management. Based on the above development, China's first GIST guideline, the "CSCO Gastrointestinal Stromal Tumor Diagnosis and Treatment Guidelines (2020 Edition)", was published. This guideline considers regional development disparities, accessibility of treatments and diagnostic methods, and the social value of cancer care, maintaining its scientific rigor, fairness, and timeliness. Over the past 30 years, the diagnosis and treatment of GIST in China significantly development. However, we should recognize that further development must require more original Chinese research, which would better benefit the Chinese population.
自1983年胃肠间质瘤（GIST）被报道以来，我国GIST诊疗的发展经历了认识、跟随到部分超越的过程。从1990年至2010年这前20年间，我国GIST诊疗从第一篇病理学综述，到2008年第一版专家共识，在GIST领域学者共同努力下为我国GIST诊疗发展奠定了基础。2010—2020年是高速发展期，除了专家共识逐版更新，在病理、外科、内科、药物监测及全程管理等GIST亚领域均有相关专家意见发布，GIST诊疗获得了极大的发展。在此基础上诞生了我国第一部GIST指南——《CSCO胃肠间质瘤诊疗指南（2020年版）》，该指南兼顾了地区发展差异、药物和诊疗手段的可及性以及肿瘤治疗的社会价值三个方面，具有科学性、公正性和时效性。近30年来，GIST的诊疗在我国取得了极大的进步，然而我们也要清醒地认识到，诊疗水平的提高仍然需要更多的中国原创研究才能更好地使中国人群患者获益。.